HPV DNA Detection for Post-treatment Surveillance of Premalignant and Malignant Lesions of Cervix

  • Dhanya S. Thomas
  • Vinotha Thomas
  • Ajit Sebastian
  • Anitha Thomas
  • Priya Abraham
  • Rachel Chandy
  • Abraham PeedicayilEmail author
Original Article



Persistence of human papilloma virus (HPV) after treatment for cervical neoplasia may be indicative of local recurrence. The aim of this study was to determine the prevalence of HPV in cervix or vagina after treatment for cervical neoplasia and to ascertain its association with local recurrence.


Data were collected retrospectively from electronic hospital medical records. The cohort consisted of women who had undergone treatment for CIN 2, CIN 3 or cervical cancer between 1 January 2014 and 31 December 2016 at a teaching hospital in India for whom post-treatment HPV results were available. Local recurrence was defined as a positive vaginal or cervical biopsy or positive radiological (PET CT) findings.


Out of a total of 101 patients, 26 had CIN 2 or 3 and 75 had cervical cancer. Post-treatment HPV was done in precancers and cancers after a mean duration of 14.9 and 8.2 months, respectively. Positive HPV detection occurred in 46.2% of precancers and 18.7% of cancers. Of the 12 precancers with positive post-treatment HPV, seven (58.3%) had recurrence, whereas among 14 cancers, three (21.4%) had recurrence. The relative risk (RR) was 4.1 (95% CI 1, 16.1) and p value 0.03 for recurrence with a positive HPV test after treatment for CIN as compared to a negative HPV result. For cancers, the RR was 3.3 (0.8, 13.9), with p = 0.09.


Positive HPV detection post-treatment is a risk factor for local recurrence in cervical neoplasia, especially in premalignant lesions. Hence, HPV testing may be useful for post-treatment surveillance.


HPV test of cure Cervical neoplasia Post-treatment surveillance 



Authors acknowledge Dr Praveen Alexander and Mr Bijesh Yadav for all scientific help.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRefGoogle Scholar
  2. 2.
    Barakat RR, Markman M, Randall M. Principles and practice of gynecologic oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.Google Scholar
  3. 3.
    Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, Powell N, Tristram A, Fiander A, Hibbitts S. Human Papillomavirus genotype testing combined with cytology as a “test of cure” post treatment: the importance of a persistent viral infection. J Clin Virol. 2011;52:88–92.CrossRefGoogle Scholar
  4. 4.
    Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol. 2016;76:S56–S61.CrossRefGoogle Scholar
  5. 5.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386386.CrossRefGoogle Scholar
  6. 6.
    Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J (2015) ICO information centre on HPV and cancer (HPV Information Centre). Hum. Papillomavirus Relat. Dis. World Summ. Rep. 4Google Scholar
  7. 7.
    Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4:e19–e27.CrossRefGoogle Scholar
  8. 8.
    Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, Shukla DK, Rath GK, Gupta PC, Swaminathan R. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 2018;19:1289–306.CrossRefGoogle Scholar
  9. 9.
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–8.CrossRefGoogle Scholar
  10. 10.
    Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168:421–5.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS, Pecorelli S. Carcinoma of the cervix uteri. Int J Gynecol Obstet. 2006;95:S43–S103.CrossRefGoogle Scholar
  12. 12.
    Koh W-J, Greer BE, Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O. Cervical cancer, version 2.2015. J Natl Compr Cancer Netw. 2015;13:395–404.CrossRefGoogle Scholar
  13. 13.
    Elit L, Fyles AW, Devries MC, Oliver TK, -Fung M, Group, GCDS. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114:528–35.CrossRefGoogle Scholar
  14. 14.
    Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466–78.CrossRefGoogle Scholar
  15. 15.
    Zanagnolo V, Ming L, Gadducci A, Maggino T, Sartori E, Zola P, Landoni F. Surveillance procedures for patients with cervical carcinoma: a review of the literature. Int J Gynecol Cancer. 2009;19:194–201.CrossRefGoogle Scholar
  16. 16.
    Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, Wharton JT. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000;78:187–93.CrossRefGoogle Scholar
  17. 17.
    Elit L, Fyles AW, Oliver TK, Aboud MC, -Fung M. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2010;17:65.CrossRefGoogle Scholar
  18. 18.
    Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv. 2004;59:543–53.CrossRefGoogle Scholar
  19. 19.
    Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004;30:205–11.CrossRefGoogle Scholar
  20. 20.
    Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol. 2009;200:422–e1.CrossRefGoogle Scholar
  21. 21.
    Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler CM, Castle PE. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Prev Biomark. 2006;15:908–14.CrossRefGoogle Scholar
  22. 22.
    Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, Runsink AP, de Schipper FA, Meijer CJ. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2003;91:67–73.CrossRefGoogle Scholar
  23. 23.
    Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, Sargent A, Wood J, Moore C, Cruickshank ME. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG Int J Obstet Gynaecol. 2008;115:1001–7.CrossRefGoogle Scholar
  24. 24.
    Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G, Bevilacqua G, Genazzani AR. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer. 2008;18:90–4.CrossRefGoogle Scholar
  25. 25.
    Costa S, Venturoli S, Origoni M, Preti M, Mariani L, Cristoforoni P, Sandri MT. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience. 2015;9:258.CrossRefGoogle Scholar
  26. 26.
    Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer. 2011;129:903–9.CrossRefGoogle Scholar
  27. 27.
    Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, Meijer CJ. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125:500–7.CrossRefGoogle Scholar
  28. 28.
    Ikenberg H, Spitz C, Schmitt B, Pfisterer J, Aisslinger U, Pfleiderer A. Human papillomavirus DNA in locally recurrent cervical cancer. Gynecol Oncol. 1994;52:332–6.CrossRefGoogle Scholar
  29. 29.
    Nagai Y, Toma T, Moromizato H, Maehama T, Asato T, Kariya K, Kanazawa K. Persistence of human papillomavirus infection as a predictor for recurrence in carcinoma of the cervix after radiotherapy. Am J Obstet Gynecol. 2004;191:1907–13.CrossRefGoogle Scholar
  30. 30.
    Song YJ, Kim J-Y, Lee S-K, Lim H-S, Lim MC, Seo S-S, Kang S, Lee DO, Park S-Y. Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer. Int J Cancer. 2011;129:896–902.CrossRefGoogle Scholar
  31. 31.
    Yu MC, Austin RM, Lin J, Beck T, Beriwal S, Comerci JT, Edwards RP, Sukumvanich P, Kelley J, Olawaiye AB. The role of high-risk human papilloma virus testing in the surveillance of cervical cancer after treatment. Arch Pathol Lab Med. 2015;139:1437–40.CrossRefGoogle Scholar
  32. 32.
    Song D, Kong W, Zhang T, Jiao S, Chen J, Han C, Liu T. The negative conversion of high-risk human papillomavirus and its performance in surveillance of cervical cancer after treatment: a retrospective study. Arch Gynecol Obstet. 2017;295:197–203.CrossRefGoogle Scholar
  33. 33.
    Agapova M, Duignan A, Smith A, O’Neill C, Basu A. Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2015;15:999–1005.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Gynaecologic OncologyChristian Medical CollegeVelloreIndia
  2. 2.Department of Clinical VirologyChristian Medical CollegeVelloreIndia

Personalised recommendations